Managing residual risk in patients receiving statin therapy

Forge, Brett H

doi:10.5694/j.1326-5377.2011.tb04159.x

Topics

To the Editor: I would like to endorse the letter by Montgomery1 questioning the efficacy of ezetimibe. As yet there are no data to support its use in clinical trials using carotid intima media thickness (CIMT) as a measure of treatment effectiveness, and there is also some evidence to suggest it could be harmful.

West Gippsland Hospital, Warragul, VIC.

Correspondence: bforge@absoluterisk.com

1. Montgomery BD. Managing residual risk in patients receiving statin therapy [letter]. Med J Aust 2010; 193: 375. <MJA full text>
2. Berneis K, Rizzo M, Berthold HK, et al. Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial. Eur Heart J 2010; 31: 1633-1639.
3. Rossebø AB, Pedersen TR, Allen C, et al. Design and baseline characteristics of the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study. Am J Cardiol 2007; 99: 970-973.
4. Hamilton-Craig IR. Managing residual risk in patients receiving statin therapy [letter]. Med J Aust 2010; 193: 375-376. <MJA full text>

Online responses are no longer available. Please refer to our instructions for authors page for more information.